| Literature DB >> 34587117 |
Jolie Barter1, Ashok Kumar1, Linda Bean1, Marissa Ciesla1, Thomas C Foster1,2.
Abstract
In order to understand the long-term effects of systemic inflammation, it is important to distinguish inflammation-induced changes in baseline cognitive function from changes that interact with aging to influence the trajectory of cognitive decline. Lipopolysaccharide (LPS; 1 mg/kg) or vehicle was administered to young adult (6 months) male rats via intraperitoneal injections, once a week for 7 weeks. Longitudinal effects on cognitive decline were examined 6 and 12 months after the initial injections. Repeated LPS treatment, in adults, resulted in a long-term impairment in memory, examined in aged animals (age 18 months), but not in middle-age (age 12 months). At 12 months following injections, LPS treatment was associated with a decrease in N-methyl-D-aspartate receptor-mediated component of synaptic transmission and altered expression of genes linked to the synapse and to regulation of the response to inflammatory signals. The results of the current study suggest that the history of systemic inflammation is one component of environmental factors that contribute to the resilience or susceptibility to age-related brain changes and associated trajectory of cognitive decline.Entities:
Keywords: LPS; NMDA receptor; hippocampus; inflammation; longitudinal; synaptic function
Mesh:
Substances:
Year: 2021 PMID: 34587117 PMCID: PMC8507275 DOI: 10.18632/aging.203588
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1Vehicle and LPS treated animals learn cue and spatial discrimination with no difference in learning or memory at 12 months, 6 months after treatment. Symbols represent mean escape path length (± SEM) for vehicle (open circles) and LPS treated (filled circles) animals over the training blocks for (A) cue and (B) spatial discrimination. (C) Box and whisker plots and individual DI scores from the acquisition, 2 hr and 24 hr probe trials. Pound sign indicates significant difference from chance (p < 0.05).
Figure 2Vehicle and LPS treated animals learn the spatial discrimination and differences in memory emerge at 18 months, 12 months after treatment. Symbols represent mean escape path length (± SEM) for vehicle (open circles) and LPS treated (filled circles) animals over the training blocks for (A) spatial discrimination. (B) Box and whisker plots and individual DI scores from the acquisition, 2 hr and 24 hr probe trials. Pound sign indicates significant difference from chance (p < 0.05). Asterisk indicates significant treatment difference (p < 0.05).
Figure 3Decreased NMDAR-mediated synaptic responses associated with prior LPS treatment. Input-output curves for the mean slope (± SEM) of the total fEPSP (A) and NMDAR-fEPSP (B) evoked by increasing stimulation voltage (V). Data is presented for the vehicle (open circles) and LPS treatment (filled circles) recorded at 18 months, 12 months after the final LPS or vehicle injection. (C) Bars illustrating mean percentage change in NMDAR fEPSP slope induced by bath application of DTT in slices obtained from LPS (n = 7/4 slices/animal) or vehicle (n = 7/4 slices/animal)-treated animals. The distribution of individual responses is also depicted.
Figure 4Differential gene expression analysis evaluating the effect of treatment in the CA1 region. Bars represent the –log (p value) for selected GO terms that were significant for down regulated (blue) and upregulated (red) genes. Dotted line is the –log (0.05).
Gene ontology categories and lists of differentially expressed genes evaluating the effect of treatment in the CA1 region.
|
|
|
|
|
|
| GOTERM_BP | GO:0008610~lipid biosynthetic process | 17 | HMGCS1, NUS1, ST8SIA4, GPAT3, HSD17B7, INPP4B, INSIG1, IGF2, IDH1, MSMO1, PEX2, PDSS1, PTGDS, PTPMT1, SELENOI, SC5D, THRSP | 0.004 |
| GOTERM_CC | GO:0060076~excitatory synapse | 15 | BCR, MAGI2, BAIAP2, GRIK5, MINK1, BSN, PPP1R9B, SH2D5, SEMA4C, LRFN1, CAMK2B, NSMF, UNC13A, DISC1, ADD2 | 0.002 |
| GOTERM_CC | GO:0014069~postsynaptic density | 14 | BCR, MAGI2, BAIAP2, GRIK5, MINK1, BSN, PPP1R9B, SH2D5, SEMA4C, LRFN1, CAMK2B, NSMF, DISC1, ADD2 | 0.004 |
| GOTERM_CC | GO:0030425~dendrite | 25 | CRTC1, GRIK5, HCFC1, COMT, KCNJ2, ZMYND8, NUMA1, HTR1A, INPP5J, ANK3, AGO2, CAMK2B, HAP1, SLC8A2, MAGI2, BAIAP2, STRN4, MINK1, BSN, PPP1R9B, ADCY9, KHSRP, NSMF, RGS8, MTOR | 0.005 |
| GOTERM_CC | GO:0045202~synapse | 28 | CRTC1, GRIK5, COMT, KCNJ2, ZMYND8, AMPH, SH2D5, ANK3, LRFN1, CAMK2B, HAP1, DISC1, SLC8A2, MAGI2, BCR, BAIAP2, RIMBP2, STRN4, MINK1, BSN, PPP1R9B, DOK7, LRP6, SEMA4C, NSMF, DOC2B, UNC13A, ADD2 | 0.008 |
| GOTERM_BP | GO:0031175~neuron projection development | 29 | CRTC1, ZMYND8, FOXO6, IGF1R, JADE2, FOLR1, UNC5A, INPP5J, ANK3, CAMSAP1, LRFN1, OBSL1, CAMK2B, MKL1, HAP1, DISC1, MAGI2, BAIAP2, LRRN2, SDK1, MINK1, NTNG2, ARID1B, PPP1R9B, SEMA4C, NSMF, MTOR, UNC13A, KIF26B | 0.02 |
| GOTERM_BP | GO:0050808~synapse organization | 13 | SEZ6L2, HTR1A, MAGI2, ANK3, MDGA1, DOK7, BSN, CAMK2B, SEZ6L, ZMYND8, UNC13A, DISC1, ADGRB2 | 0.02 |
Figure 5Western blot analysis of NMDAR subunit expression in CA1 region of hippocampus. The blots illustrate expression of (A) GluN2B, (B) GluN2A, and PSD95. (C) The bars represent the mean (± SEM) ratio of expression for vehicle (n = 4) and LPS treated (n = 4) animals.
Figure 6Schematic representing the experimental paradigm for the longitudinal effect of systemic inflammation on cognition. Young (6 months) male Fischer 344 X Brown Norway hybrid rats were either injected with vehicle (n = 16) or LPS (n = 16) once a week for 7 weeks. A subset of animals (vehicle n = 12; LPS n = 12) were cognitively assessed on the spatial discrimination water maze task at 12 and 18 months of age. Hippocampal tissue from behaviorally characterized rats was collected one week after completion of behavioral testing, at 18 months of age, and RNA sequencing was performed on the CA1 region of the hippocampus. The other group of animals (vehicle n = 4; LPS n = 4) were not behaviorally characterized and were used for electrophysiological experiments at 18 months of age (12 months after the injections).